102
Participants
Start Date
September 5, 2016
Primary Completion Date
April 25, 2018
Study Completion Date
April 25, 2018
Viaskin PT 25 mcg
Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
Viaskin PT 50 mcg
Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
Viaskin PT Placebo
Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
Boostrix™
Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
Center for Vaccinology Medical faculty UNIGE and University of Geneva (HUG), Geneva
Lead Sponsor
University Hospital, Geneva
OTHER
DBV Technologies
INDUSTRY